Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading update

14 Jan 2021 07:00

RNS Number : 6200L
Elementis PLC
14 January 2021
 

Elementis plc

Trading Update

Sequential revenue improvement, FY 20 adjusted operating profit $81-83m

Significant reduction in net debt, anticipated to be under $415m

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 December 2020.

Fourth quarter business performance

 

Fourth quarter revenue is expected to be ahead of the third quarter driven by improved volumes and largely stable pricing. Overall performance in the quarter is anticipated to be in line with management expectations, helped by tight cost management and supply chain efficiencies. As a result, adjusted operating profit for 2020 is expected to be $81-83m.

· Coatings has continued to perform well in Q4, albeit at lower levels than the prior year period, and remains on track to deliver improved operating margins versus the prior year.

 

· Personal Care sales remain materially lower than the prior year period in both Cosmetics and AP Actives, due to the continuation of COVID-19 related social and travel restrictions that have reduced consumption. Q4 performance is anticipated to be in line with Q3 levels. 

 

· Talc volumes continued to recover, driven by improved long-life plastic demand for automotive applications and resilience in coatings. As a result, Q4 revenue is expected to be ahead of the prior year period.

· Chromium demand has sequentially improved, driven by increased demand for industrial applications such as leather tanning and metal plating. As a result, Q4 revenue is anticipated to be broadly in line with the prior year period.

 

· Energy continues to experience very weak market conditions with rig counts and activity levels remaining subdued.

 

In the fourth quarter we have continued to deliver against our Innovation, Growth and Efficiency strategy. For full year 2020 we launched 12 new products, captured over $30m of new business and delivered $15m of in year cost savings.

For 2021, whilst our new business and innovation pipelines are encouraging, we continue to face temporary demand challenges from COVID-19, particularly in Personal Care where we expect performance will recover when social and travel restrictions are lifted. As a result of the recently announced closure of our plant in Charleston, West Virginia, we have made further progress underpinning $10m of supply chain cost efficiencies, and our new AP Actives plant in India remains on track for mid-2021 start up.

Liquidity and balance sheet

 

As result of tight working capital management and disciplined capital expenditure, net debt* at the end of 2020 is anticipated to be under $415m, representing a significant reduction from $454m at the start of the year.

 

Elementis has a proven cash generative business model, with average operating cash conversion above 90% over the last 3 years, and the Group continues to operate with ample liquidity, with over $300m immediately available through committed lending facilities.

 

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

David Allchurch

 

* Excluding IFRS 16 impact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGMMRFGGMZM
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.